Inadequate detection of the FSHR complicates future research on extragonadal FSHR localization

Victoria N. Tedjawirja*, Gerrit K. J. Hooijer, C. Dilara Savci-Heijink, Kristina Kovac, Ron Balm, Vivian de Waard

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Introduction: Recently, follicle stimulating hormone (FSH) through interaction with its receptor (FSHR) has been proposed to play a role in postmenopausal osteoporosis and cardiovascular disease, rather than the loss of estrogen. To explore this hypothesis, unravelling which cells express extragonadal FSHR on protein level is key. Methods: We used two commercial anti-FSHR antibodies and validated them by performing immunohistochemistry on positive (ovary, testis) and negative controls (skin). Results: The monoclonal anti-FSHR antibody could not identify the FSHR in ovary or testis. The polyclonal anti-FSHR antibody stained the granulosa cells (ovary) and Sertoli cells (testis), yet there was equally intense staining of other cells/extracellular matrix. Furthermore, the polyclonal anti-FSHR antibody also stained skin tissue extensively, suggesting that the antibody stains more than just FSHR. Discussion: The findings in this study may add accuracy to literature on extragonadal FSHR localization and warrants attention to the use of inadequate anti-FSHR antibodies to value the potential role of FSH/FSHR in postmenopausal disease.
Original languageEnglish
Article number1095031
JournalFrontiers in Endocrinology
Publication statusPublished - 2023

Cite this